Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study
You may also be interested in...
And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market
The first company to enter the drug-eluting stent market will now be the first to depart.
And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market
The first company to enter the drug-eluting stent market will now be the first to depart.
Angiotech and Conor settle
Angiotech reaches "favorable" agreement with Johnson & Johnson/Conor Medsystems Sept. 17 to settle all patent litigation ongoing since 2005 related to its paclitaxel-eluting stent technology. Angiotech licenses the patents in question exclusively to Boston Scientific for its Taxus stent. Johnson & Johnson discontinued development of the patent-relevant CoStar paclitaxel-eluting stent and terminated sales of the product overseas in May following disappointing trial results (1"The Gray Sheet" May 14, 2007, p. 9). The settlement covers all ongoing litigation in the UK, the Netherlands and Australia (2"The Gray Sheet" Jan. 22, 2007, p. 12)